4/23
11:04 pm
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
4/22
08:03 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
Low
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
4/8
08:14 am
ctmx
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors [Yahoo! Finance]
Low
Report
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors [Yahoo! Finance]
4/8
08:00 am
ctmx
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Low
Report
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
4/3
08:24 am
ctmx
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas [Yahoo! Finance]
Neutral
Report
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas [Yahoo! Finance]
4/3
08:00 am
ctmx
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Low
Report
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
3/21
08:14 am
ctmx
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors [Yahoo! Finance]
Low
Report
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors [Yahoo! Finance]
3/21
08:00 am
ctmx
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Low
Report
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
3/18
08:17 am
ctmx
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas [Yahoo! Finance]
3/18
08:00 am
ctmx
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Medium
Report
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
3/13
07:16 am
ctmx
CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
3/12
08:52 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/11
07:01 pm
ctmx
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates [Yahoo! Finance]
Medium
Report
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates [Yahoo! Finance]
3/11
04:50 pm
ctmx
FLEX, OCUL and PRPL are among after hour movers [Seeking Alpha]
Low
Report
FLEX, OCUL and PRPL are among after hour movers [Seeking Alpha]
3/11
04:17 pm
ctmx
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/11
04:10 pm
ctmx
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
High
Report
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
3/4
08:00 am
ctmx
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Low
Report
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
2/27
08:04 am
ctmx
CytomX Therapeutics to Present at Upcoming March Investor Conferences [Yahoo! Finance]
High
Report
CytomX Therapeutics to Present at Upcoming March Investor Conferences [Yahoo! Finance]
2/27
08:00 am
ctmx
CytomX Therapeutics to Present at Upcoming March Investor Conferences
High
Report
CytomX Therapeutics to Present at Upcoming March Investor Conferences
2/13
06:06 am
ctmx
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29% [Yahoo! Finance]
Medium
Report
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29% [Yahoo! Finance]